Recent Updates
Recently added Catalysts

Listaftoclax

Phase 1

Advanced Chronic Myeloid Leukemia | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Mar 12, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06401603A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaPHASE1 RECRUITING 30 — — Aug 6, 2024Jan 1, 2029Mar 12, 20261 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
DecitabineDRUGGiven by IV
ListaftoclaxDRUGGiven by PO
OlverembatinibDRUGGiven by PO
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06401603studyFirstPostDate: changed